secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2022-09-12T23:59:59+00:00
Accession:  0001193125-22-242398
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD CEO departs; co-founder & CBO named interim co-CEOs; strategic review ongoing
--------------------------------------------------------------------------------

- CEO Hugh O'Dowd departed Sept 6, 2022; termination without 'Good Cause' triggers severance.
- Dr. Brian Bernick (co-founder, Chief Scientific/Medical Officer) and Mark Glickman (Chief Business Officer) named Interim Co-CEOs.
- Tommy Thompson, former Chairman since 2012, appointed Executive Chairman.
- Press release states the Company continues its robust strategic alternatives process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/0001193125-22-242398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000119312522242398/d395778d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-242398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer